Compare
DaVita Inc. vs Progyny, Inc. vs Sotera Health Co vs Viemed Healthcare, Inc.
| Latest fiscal year | DaVita Inc. DVA | Progyny, Inc. PGNY | Sotera Health Co SHC | Viemed Healthcare, Inc. VMD |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $13.64B | $1.29B | $1.16B | $270.28M |
| Revenue growth (YoY) | +6.5% | +10.4% | +5.7% | +20.5% |
| Gross margin | n/a | 23.6% | 55.5% | 57.5% |
| Operating margin | 15.0% | 6.6% | n/a | 8.5% |
| Net margin | 5.5% | 4.5% | 6.7% | 5.5% |
| Net income | $746.80M | $58.52M | $77.95M | $14.93M |
| EPS (Diluted) | $9.84 | $0.65 | $0.27 | $0.37 |
| Operating cash flow | $1.89B | $210.19M | $287.19M | $51.92M |
| Free cash flow | $1.31B | $191.78M | $149.18M | $11.93M |
| Cash & equivalents | $676.44M | $112.24M | $344.62M | $13.50M |
| Total assets | $17.48B | $742.43M | $3.26B | $199.15M |
| Total liabilities | $16.32B | $226.39M | $2.66B | $55.63M |
| Shareholders' equity | -$651.08M | $516.04M | $606.03M | $141.54M |
| Return on year-end equity | n/a | 11.3% | 12.9% | 10.6% |
| Shares outstanding | 68.55M | 83.37M | n/a | 38.02M |
Revenue, most recent five fiscal years
| Fiscal year | DaVita Inc. | Progyny, Inc. | Sotera Health Co | Viemed Healthcare, Inc. |
|---|---|---|---|---|
| Latest | $13.64B Ended 2025-12-31 | $1.29B Ended 2025-12-31 | $1.16B Ended 2025-12-31 | $270.28M Ended 2025-12-31 |
| 1 year earlier | $12.82B Ended 2024-12-31 | $1.17B Ended 2024-12-31 | $1.10B Ended 2024-12-31 | $224.26M Ended 2024-12-31 |
| 2 years earlier | $12.14B Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $1.05B Ended 2023-12-31 | $183.01M Ended 2023-12-31 |
| 3 years earlier | $11.61B Ended 2022-12-31 | $786.91M Ended 2022-12-31 | $1.00B Ended 2022-12-31 | $138.83M Ended 2022-12-31 |
| 4 years earlier | $11.62B Ended 2021-12-31 | $500.62M Ended 2021-12-31 | $931.48M Ended 2021-12-31 | $117.06M Ended 2021-12-31 |